Metrion Biosciences appoints Dr Steve Jenkinson as VP, Drug Discovery and Safety Assessment to strengthen US operations

Metrion Biosciences Ltd (“Metrion”), the specialist ion channel contract research and drug discovery company, today announced the appointment of Dr. Steve Jenkinson as Vice President, Drug Discovery and Safety Assessment. The US-based appointment represents an important step in the expansion of Metrion’s business, driven by its ion channel discovery capabilities.

Steve will be responsible for supporting Metrion’s growing client base across the US, guiding projects, and navigating key milestones. He has a strong background in drug discovery and secondary pharmacology, including the management of drug discovery programmes across multiple therapeutic areas and stages, ranging from target identification to the nomination of candidates for preclinical development.

Steve has spent over 25 years in leadership positions driving drug discovery projects for GSK and Tanabe Research Laboratories. He joins Metrion from Pfizer where, as Senior Director, he established, developed and led the secondary pharmacology and high throughput screening team. Steve was also previously co-chair of the IQ DruSafe Secondary Pharmacology working group and a member of the FDA’s HESI Pro-Arrhythmia group. He has completed two postdoctoral research fellowships, at the Scripps Institute in La Jolla and at the Neurosciences Institute in San Diego, received his undergraduate degree in pharmacology from the University of Glasgow and PhD in molecular pharmacology from the University of Leicester. He also completed a master’s degree in clinical research at the University of California, San Diego.

We are very pleased to welcome Steve to the Metrion team. His background in both drug discovery and safety pharmacology will be pivotal in supporting our clients in the US, enhancing Metrion’s scientific leadership in this key territory.

Dr Andy Southan, Chief Executive, Metrion Biosciences

This is an exciting time for Metrion, I am delighted to be part of a service provider on such an impressive growth trajectory and to be offered the opportunity to support and enhance the Company’s offering to its growing US client base.

Dr Steve Jenkinson, VP, Drug Discovery and Safety Assessment, Metrion Biosciences

For more information: https://www.metrionbiosciences.com/

Citations

Please use one of the following formats to cite this article in your essay, paper or report:

  • APA

    Metrion Biosciences Limited. (2023, June 12). Metrion Biosciences appoints Dr Steve Jenkinson as VP, Drug Discovery and Safety Assessment to strengthen US operations. News-Medical. Retrieved on June 15, 2024 from https://www.news-medical.net/news/20230612/Metrion-Biosciences-appoints-Dr-Steve-Jenkinson-as-VP-Drug-Discovery-and-Safety-Assessment-to-strengthen-US-operations.aspx.

  • MLA

    Metrion Biosciences Limited. "Metrion Biosciences appoints Dr Steve Jenkinson as VP, Drug Discovery and Safety Assessment to strengthen US operations". News-Medical. 15 June 2024. <https://www.news-medical.net/news/20230612/Metrion-Biosciences-appoints-Dr-Steve-Jenkinson-as-VP-Drug-Discovery-and-Safety-Assessment-to-strengthen-US-operations.aspx>.

  • Chicago

    Metrion Biosciences Limited. "Metrion Biosciences appoints Dr Steve Jenkinson as VP, Drug Discovery and Safety Assessment to strengthen US operations". News-Medical. https://www.news-medical.net/news/20230612/Metrion-Biosciences-appoints-Dr-Steve-Jenkinson-as-VP-Drug-Discovery-and-Safety-Assessment-to-strengthen-US-operations.aspx. (accessed June 15, 2024).

  • Harvard

    Metrion Biosciences Limited. 2023. Metrion Biosciences appoints Dr Steve Jenkinson as VP, Drug Discovery and Safety Assessment to strengthen US operations. News-Medical, viewed 15 June 2024, https://www.news-medical.net/news/20230612/Metrion-Biosciences-appoints-Dr-Steve-Jenkinson-as-VP-Drug-Discovery-and-Safety-Assessment-to-strengthen-US-operations.aspx.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Metrion Biosciences and The KCNC1 Foundation Collaborate on New Ion Channel Modulators